{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:38:45Z","timestamp":1787503125024,"version":"build-2736575974"},"reference-count":61,"publisher":"Informa UK Limited","issue":"1","funder":[{"DOI":"10.13039\/100000002","name":"the NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003187","name":"NSF DMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003187","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Challenge Grant award from Research to Prevent Blindness, NY","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Targets"],"published-print":{"date-parts":[[2022,1,2]]},"DOI":"10.1080\/14728222.2022.2030706","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T05:24:47Z","timestamp":1642742687000},"page":"5-12","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":45,"title":["Disease progression pathways of wet AMD: opportunities for new target discovery"],"prefix":"10.1080","volume":"26","author":[{"given":"Amber T.","family":"Wolf","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alon","family":"Harris","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Oddone","sequence":"additional","affiliation":[{"name":"Glaucoma Unit, IRCCS Fondazione Bietti, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Siesky","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Verticchio Vercellin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5557-6777","authenticated-orcid":false,"given":"Thomas A.","family":"Ciulla","sequence":"additional","affiliation":[{"name":"Retina Department, Midwest Eye Institute, Indianapolis, IN, USA"},{"name":"Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA"},{"name":"Medical Department, Clearside Biomedical, Alpharetta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70145-1"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1636031"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.3109\/15569527.2015.1124886"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2014.884559"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2017.08.008"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2016.02.028"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3180a032db"},{"issue":"9","key":"cit0008","first-page":"Cd011230","volume":"9","author":"Moja L","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"cit0009","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.17-23189","volume":"58","author":"Daniel E","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102673"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.03.046"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2017.04.004"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077117"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2019.1667333"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.18.9764"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100687"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2020.11.004"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1177\/0192623320968079"},{"key":"cit0020","unstructured":"Roche. Roche\u2019s port delivery system with ranibizumab shows positive phase III results in neovascular age-related macular degeneration Accessed July 2021. Published 2020. https:\/\/www.roche.com\/investors\/updates\/inv-update-2020-05-27.htm"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1177\/25158414211027708"},{"key":"cit0022","volume-title":"Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation and Degeneration 2021 Annual Meeting","author":"Kodiak"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1039\/C9BM01049A"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2017.1356817"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.visres.2007.07.027"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1038\/nri1224"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.03.006"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2021.0001"},{"key":"cit0029","unstructured":"Adverum. Adverum Presents 2-Year OPTIC Data Demonstrating Sustained Durability and Promising Safety Profile from Single Intravitreal Injection of ADVM-022 in Wet AMD Patients Who Previously Required Frequent Anti-VEGF Injections. Published 2021. Accessed February 2022. https:\/\/investors.adverum.com\/news\/news-details\/2021\/Adverum-Presents-2-Year-OPTIC-Data-Demonstrating-Sustained-Durability-and-Promising-Safety-Profile-from-Single-Intravitreal-Injection-of-ADVM-022-in-Wet-AMD-Patients-Who-Previously-Required-Frequent-Anti-VEGF-Injections\/default.aspx"},{"key":"cit0030","unstructured":"REGENXBIO. REGENXBIO ANNOUNCES DOSING OF FIRST PATIENT IN PHASE II AAVIATE\u2122 TRIAL OF RGX-314 FOR THE TREATMENT OF WET AMD USING SUPRACHOROIDAL DELIVERY. Published 2020. [cited 2021 Sep 7]. https:\/\/regenxbio.gcs-web.com\/news-releases\/news-release-details\/regenxbio-announces-dosing-first-patient-phase-ii-aaviatetm"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13020288"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1159\/000088637"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.10.014"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.08.011"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.10.008"},{"issue":"2","key":"cit0036","first-page":"105","volume":"4","author":"Homayouni M","year":"2009","journal-title":"J Ophthalmic Vis Res"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-021-00325-5"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1097\/APO.0000000000000291"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2006.22.213"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-019-1474-0"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14340-x"},{"key":"cit0042","unstructured":"Graybug Vision. Graybug vision completes treatment phase of ALTISSIMO trial in wet AMD with 12-Month topline data. Published 2021. [cited 2021 Jul 7]. https:\/\/eyewire.news\/articles\/graybug-vision-completes-treatment-phase-of-altissimo-trial-in-wet-amd-with-12-month-topline-data"},{"key":"cit0043","unstructured":"Graybug Vision. Our technologies and pipeline Accessed July 2021. Published 2021. https:\/\/www.graybug.vision\/our-technologies-and-pipeline\/#pipeline"},{"key":"cit0044","unstructured":"EyePoint Pharma. EyePoint pharma pipeline. 2021 Accessed July 2021 https:\/\/eyepointpharma.com\/pipeline."},{"key":"cit0045","unstructured":"Kunzmann K. Vorolanib via durasert provides safe treatment of wet AMD through 12 months. Published 2021. [cited 2021 Nov 20]. https:\/\/www.hcplive.com\/view\/vorolanib-via-durasert-safe-treatment-wet-amd-12-months"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.10.7.19"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2016.02.010"},{"key":"cit0048","unstructured":"Clearside Biomedical. Clearside biomedical announces positive safety results from cohort 1 of OASIS phase 1\/2a clinical trial of CLS-AX (axitinib injectable suspension) for the treatment of wet AMD 2021 Accessed July 2021. https:\/\/ir.clearsidebio.com\/news-releases\/news-release-details\/clearside-biomedical-announces-positive-safety-results-cohort-1"},{"key":"cit0049","unstructured":"Ocular Therapeutix. OCULAR THERAPEUTIX\u2122 ANNOUNCES UPCOMING PRESENTATION OF INTERIM OTX-TKI PHASE 1 CLINICAL TRIAL DATA AT ANGIOGENESIS, EXUDATION, AND DEGENERATION 2021 \u2013 VIRTUAL EDITION 2021 Accessed July 2021. https:\/\/ocutx.gcs-web.com\/news-releases\/news-release-details\/ocular-therapeutixtm-announces-upcoming-presentation-interim-otx"},{"key":"cit0050","volume-title":"Subjects with Neovascular Age-Related Macular Degeneration. RETINA SOCIETY ANNUAL SCIENTIFIC MEETING","author":"Avery RL WJ","year":"2020"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201505889"},{"key":"cit0052","unstructured":"Roche. Roche\u2019s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degeneration. 2020 Accessed July 2021 https:\/\/www.roche.com\/media\/releases\/med-cor-2020-12-21.htm."},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-020-00250-z"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1172\/JCI74527"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2020.107972"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.710186"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.100966"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2018.11.022"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1763953"},{"key":"cit0060","unstructured":"SciFluor Life Sciences. SciFluor announces positive topline results of phase 1\/2 study of SF0166 eye drops to treat wet AMD. Published 2017. [cited 2021 Jul 7]. https:\/\/www.businesswire.com\/news\/home\/20171218005625\/en\/SciFluor-Announces-Positive-Top-Line-Results-of-Phase-12-Study-of-SF0166-Eye-Drops-to-Treat-Wet-Age-Related-Macular-Degeneration"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.6b00056"}],"container-title":["Expert Opinion on Therapeutic Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728222.2022.2030706","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T04:55:25Z","timestamp":1680065725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728222.2022.2030706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,2]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,2]]}},"alternative-id":["10.1080\/14728222.2022.2030706"],"URL":"https:\/\/doi.org\/10.1080\/14728222.2022.2030706","relation":{},"ISSN":["1472-8222","1744-7631"],"issn-type":[{"value":"1472-8222","type":"print"},{"value":"1744-7631","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iett20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iett20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-08-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}